Application of panax notoginseng saponins in preparing NLRP3 inflammasome-restraining drugs or drugs for treating tristimania
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- NANHUA UNIV
- Publication Date
- 2018-12-07
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the technical field of new application of drugs, in particular to the application of Panax notoginseng saponins in the preparation of drugs for inhibiting NLRP3 inflammasomes or drugs for treating depression. Background technique
[0002] The NLRP3 inflammasome has the function of regulating the chronic inflammatory response of the body, and its composition includes NLRP3 (NLRfamily, pyrin domain containing 3), apoptosis-associated speck-like protein containing CARD (ASC) and cysteine day Cysteine-requiring aspartate protease-1 (Caspase-1), a cytoplasmic sensor of endogenous or exogenous danger signals, is a molecular platform for activating caspase-1, and regulates interleukin- Maturation and secretion of pro-inflammatory cytokines such as 1β (Interleukin-1β, IL-1β) and IL-18.
[0003] NLRP3 is one of the danger signal receptors in innate immune cells, which can be activated by various pathogen-associated molecular patterns...